Full text is available at the source.
Abstract
Retatrutide, an agonist of GIP, GLP-1, and glucagon receptors, is under investigation for treating obesity and type 2 diabetes.
- Retatrutide may help in managing obesity and type 2 diabetes.
- The drug is also being assessed for its potential effects on knee osteoarthritis and obstructive sleep apnoea.
- Efficacy and safety in adults with obesity and type 2 diabetes are the primary focus of the ongoing investigation.
Simplified